Jamie Rister, MD
Sports Medicine · Alexandria, LANPI 1770801763
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Arthrex at 56.8% of the total. Reporting peaked in 2021 at $12,126 and has fallen 70.6% since, to $3,563 in 2025.
Across 138 payments — averaging $186.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$15K
- ALON Medical Technology$8K
- Stryker$2K
- Johnson & Johnson$401
- Ortho Development Corporation$100
- Zimmer Biomet$51
- plus $83 from 4 others
What the payments were for
- Speaking & faculty fees$10,50041%
- Travel & lodging$4,74118%
- Food & beverage$4,66118%
- Education$5,78923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 59 | $14,580 |
| ALON Medical Technology | 44 | $8,166 |
| Stryker | 24 | $2,310 |
| Johnson & Johnson | 5 | $401 |
| Ortho Development Corporation | 1 | $100 |
| Zimmer Biomet | 1 | $51 |
| GE HealthCare | 1 | $26 |
| Vericel Corporation | 1 | $21 |
| Pfizer | 1 | $18 |
| Innovation Technologies Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,691 in reported general payments places this provider in the 85th percentile of 82 sports medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 131 | $976 |
| Meloxicam | 177 | $698 |
| Methocarbamol | 87 | $681 |
| Celecoxib | 45 | $551 |
| Cephalexin | 149 | $443 |
| Gabapentin | 29 | $287 |
| Tizanidine Hcl | 39 | $231 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Alexandria
- Michael LeddyAlexandria$44K
- Phillip BacillaAlexandria$6K
- Felix SavoieNew Orleans$1.4M
- Misty SuriNew Orleans$1.2M
- Michael ObrienNew Orleans$391K
- Brett CascioLake Charles$82K
- Brian GodshawNew Orleans$69K
- Andrew GottschalkJefferson$45K
- Steven JonesHammond$38K
- Mario Lobao GoncalvesShreveport$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.